Oral Treatment of Cowpox and Vaccinia Virus Infections in Mice with Ether Lipid Esters of Cidofovir

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 2, 2004, Pages 404-412

  Quenelle, Debra C ^a   Collins, Deborah J ^a   Wan, W Brad ^b   Beadle, James R ^b   Hostetler, Karl Y ^b   Kern, Earl R ^a,c  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CIDOFOVIR; CIDOFOVIR DERIVATIVE; CIDOFOVIR ETHER LIPID ESTER; CYTOSINE; DRUG DERIVATIVE; ETHER DERIVATIVE; HEXADECYLOXYPROPYLCIDOFOVIR; LIPID; OCTADECYLOXYETHYLCIDOFOVIR; OLEYLOXYETHYLCIDOFOVIR; OLEYLOXYPROPYLCIDOFOVIR; ORGANOPHOSPHORUS COMPOUND; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CHEMISTRY; COMPARATIVE STUDY; CONTROLLED STUDY; COWPOX; COWPOX VIRUS; DRUG EFFECT; DRUG EFFICACY; DRUG STRUCTURE; FEMALE; KIDNEY; LIVER; LUNG; MORTALITY; MOUSE; MOUSE STRAIN; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SINGLE DRUG DOSE; SPLEEN; VACCINIA; VACCINIA VIRUS; VIROLOGY; VIRUS INFECTION; VIRUS LOAD; VIRUS PATHOGENESIS; VIRUS REPLICATION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-HIV AGENTS; COWPOX; COWPOX VIRUS; CYTOSINE; ETHERS; FEMALE; LIPIDS; MICE; MICE, INBRED BALB C; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; VACCINIA; VACCINIA VIRUS; VIRAL LOAD; VIRUS REPLICATION;

EID: 0942301302     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.2.404-412.2004     Document Type: Article

References (26)

1. 14C] cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism. Mol. Pharmacol. 63:678-681.
2. Beadle, J. R., C. Hartline, K. A. Aldern, N. Rodriguez, E. Harden, E. R. Kern, and K. Y. Hostetler. 2002. Alkoxyalkyl esters of cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob. Agents Chemother 46:2381-2386.
3. Bray, M., M. Martinez, D. F. Smee, D. Kefauver, E. Thompson, and J. W. Huggins. 2000. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J. Infect. Dis. 181:10-19.
4. Bray, M., M. Martinez, D. Kefauver, M. West, and C. Roy. 2002. Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir. Antivir. Res. 54:129-142.
5. Centers for Disease Control and Prevention. 2003. Multistate outbreak of monkeypox-Illinois, Indiana, and Wisconsin, 2003. Morb. Mortal. Wkly. Rep. 52:537-540.
6. Ciesla, S. L., J. Trahan, W. B. Wan, J. R. Beadle, K. A. Aldern, G. R. Painter, and K. Y. Hostetler. 2003. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antivir. Res. 59:163-171.
7. Cundy, K. C., A. M. Bidgood, G. Lynch, J. P. Shaw, L. Griffin, and W. A. Lee. 1996. Pharmacokinetics, bioavailability, metabolism, and tissue distribution of cidofovir (HPMPC) and cyclic HPMPC in rats. Drug Metab. Dispos. 24:745-752.
8. De Clereq, E., T. Sakuma, M. Baba, R. Pauwels, J. Balzarini, I. Rosenberg, and A. Holy. 1987. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antivir. Res. 8:261-272.
9. De Clercq, E., and J. Neyts. 1993. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxy-propyl) cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (scid) mice. J. Med. Virol. 41:242-246.
10. Heymann, D. L., M. Szczeniowski, and K. Esteves. 1988. Re-emergence of monkeypox in Africa: a review of the past six years. Br. Med. Bull. 54:693-702.
11. Hostetler, K. Y., J. R. Beadle, G. D. Kini, M. F. Gardner, K. N. Wright, T.-H. Wu, and B. E. Korba. 1997. Enhanced oral absorption and antiviral activity of 1-O-octadecyl-sn-glycero-3-phospho-acyclovir and related compounds in hepatitis B virus infection, in vitro. Biochem. Pharmacol. 53:1815-1822.
12. Hostetler, K. Y., J. R. Beadle, W. E. Hornbuckle, C. A. Bellezza, I. A. Toehkov, P. J. Cote, J. L. Gerin, B. E. Korba, and B. C. Tennant. 2000. Antiviral activities of oral 1-O-hexadecylpropanediol-3-phospho-ganciclovir and acyclovir in woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob. Agents Chemother. 44:1964-1969.
13. Hostetler, K. Y., R. J. Rybak, J. R. Beadle, M. F. Gardner, K. A. Aldern, K. N. Wright, and E. R. Kern. 2001. In vitro and in vivo activity of 1-O-hexadecyl-propanediol-3-phospho-ganciclovir and 1-O-hexadecylpropanediol-3-phospho-penciclovir in cytomegalovirus and herpes simplex virus infections. Antivir. Chem. Chemother. 12:61-70.
14. Jacobson, M. A., S. Wilson, H. Stanley, C. Holtzer, J. Cherrington, and S. Safrin. 1999. Phase 1 study of combination therapy with intravenous cidofovir and oral gangciclovir for cytomegalovirus retinitis in patients with AIDS. Clin. Infect. Dis. 28:528-533.
15. Kern, E. R., C. Hartline, E. Harden, K. Keith, N. Rodriguez, J. R. Beadle, and K. Y. Hostetler. 2002. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob. Agents Chemother. 46:991-995.
16. LeDuc, J. W., I. Damon, D. A. Relman, J. Huggins, and P. B. Jahrling. 2002. Smallpox research activities: U. S. interagency collaboration, 2001. Emerg. Infect. Dis. 8:743-745.
17. LeDue, J. W., and P. B. Jahrling. 2001. Strengthening national preparedness for smallpox: an update. Emerg. Infect. Dis. 7:155-157.
18. Quenelle, D. C., D. J. Collins, and E. R. Kern. 2003. Efficacy of multiple and single dose cidofovir in vaccinia and cowpox virus infections of mice. Antimicrob. Agents Chemother. 47:3275-3280.
19. Rybak, R. J., J. Zemlika, Y. Qiu, C. B. Hartline, and E. R. Kern. 1999. Effective treatment of murine cytomegalovirus infections with methlenecyclopropane analogues of nucleosides. Antivir. Res. 43:175-188.
20. Smee, D. F., K. W. Bailev, and R. W. Sidwell. 2001. Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir. Antivir. Chem. Chemother. 12:71-76.
21. Smee, D. F., K. W. Bailey, and R. W. Sidwell. 2000. Treatment of cowpox vaccinia virus respiratory infections in mice with ribavirin as a single agent or followed sequentially by cidofovir. Antivir. Chem. Chemother. 11:303-309.
22. Smee, D. F., K. W. Bailey, M. H. Wong, and R. W. Sidwell. 2000. Treatment of cowpox virus respiratory infections in mice with ribavirin as a single agent or followed sequentially by cidofovir. Antivir. Chem. Chemother. 11:303-309.
23. Smee, D. F., K. W. Bailey, M. H. Wong, and R. W. Sidwell. 2000. Intranasal treatment of cowpox virus respiratory infections in mice with cidofovir. Antivir. Res. 47:171-177.
24. Smee, D. F., K. W. Bailey, M. H. Wong, and R. W. Sidwell. 2001. Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice. Antivir. Res. 52:55-62.
25. Snoeck, R., A. Holý, C. Dewolf-Peeters, J. Van Den Oord, E. DeClercq, and G. Andrei. 2002. Antivaccinia activities of acyclic nucleoside phosphonate derivatives in epithelial cells and organotypic cultures. Antimicrob. Agents Chemother. 46:3356-3361.
26. Wachsman, M., B. G. Petty, K. C. Cundy, H. S. Jaffe, P. E. Fisher, A. Pastelak, and P. S. Lietman. 1996. Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human immunodeficiency virus-infected subjects. Antivir. Res. 29:153-161.